Pharmathen fully equips the new scientific laboratory of the 3rd Gymnasium of Gerakas
Pharmathen acquires CBL Patras
Pharmathen excels at this year’s Growth Awards in Research and Innovation
Dutch court halts sale of Pharmathen cancer drug Okrodin in Europe
Our Group CEO, Dimitris Kadis, is featured in Kathimerini special edition “New Challenges, New Horizons”
Pharmathen’s 200 million euros investment plan, increased by 50 million euros for the next five years period 2022-2026
CVC Credit supports the acquisition of Pharmathen by Partners Group
From 9th to 11th November 2021, we had the pleasure of meeting with our global partners in person again. We would like to extend our appreciation to all customers and partners from around the globe who visited our booth and thank them for their loyalty and for putting their trust in Pharmathen!
We are very excited to announce that after a forced break in 2020, we will be exhibiting at the CPhI Worldwide in Milan, from 9th to 11th November 2021. We look forward to the opportunity to meet with our global partners around the world in person again and present our attractive portfolio and pipeline with the overall aim of complementing our partners' needs and improving the quality of life of millions of people around the world.
Partners Group has agreed to acquire a European pharmaceutical company, Pharmathen, from the international investment firm BC Partners for an enterprise value of approximately $1.9bn (€1.6bn).